Jasper Therapeutics Trade Higher As New Briquilimab Data Shows Safety, Efficacy In Blood Cancer Patients

  • Jasper Therapeutics Inc JSPR announced that new data for briquilimab (formerly JSP191) will be presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place next month.
  • The studies demonstrate that a regimen of briquilimab plus Flu/TBI leads to successful engraftment of donor blood stem cell without the usual short and long-term toxicities accompanying alternative busulfan-based regimens commonly used in the transplant of donor or gene-corrected cells. 
  • Related: Jasper Therapeutics Announces Development Prioritization of Briquilimab In Chronic Diseases.
  • The company says that briquilimab can potently synergize with radiation, amplifying its stem cell-depleting effects without increasing off-target toxicity.
  • The first abstract demonstrates that briquilimab was safe, well-tolerated, and achieved durable remissions in 8 of 12 first-treated AML patients. 
  • All eight patients were relapse-free at one-year follow-up. Six of 9 patients who entered transplant with detectable AML showed long-term eradication of the AML clones at one-year. 
  • In a companion abstract, 29 AML and MDS patients treated with briquilimab and Flu/TBI demonstrated lower-than-expected rates of acute and chronic graft-versus-host disease (GVHD). 
  • Price Action: JSPR shares are up 49.65% at $2.50 on the last check Friday.
  • Photo Via Company
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!